https://www.selleckchem.com/ph....armacological_epigen
The AMPLIFY trial found significantly lower major bleeding (M and similar recurrent venous thromboembolism (VTE) risks associated with apixaban vs warfarin among patients with VTE. To compare MB, clinically-relevant non-major (CRNM) bleeding, and recurrent VTE risks among clinically-relevant subgroups of newly diagnosed elderly patients with VTE prescribed apixaban vs warfarin. US Medicare patients prescribed apixaban or warfarin within 30days post-VTE encounter were identified. Propensity score matching (PSM) was used to c
Like
Comment
Share
